MiR-21 promotes hepatic steatosis and fibrosis by targeting peroxisome proliferator-activated receptor alpha (PPARα) and activating hepatic stellate cells (HSCs) [24,25,26]. This evidence concerns the gene PPARA and fatty liver disease.